Arcellx Inc
ACLX71.770USD
+0.630+0.89%
交易中 （美东）报价延迟15分钟
3.95B总市值
亏损市盈率 TTM
关于 Arcellx Inc 公司
Arcellx, Inc. 是一家临床阶段的生物技术公司。该公司专注于开发可控细胞疗法，用于治疗癌症和其他无法治愈的疾病患者。该公司的主要项目是针对 BCMA 的 ddCAR 产品候选药物 CART-ddBCMA，该产品正在其关键的 II 期 iMMagine-1 试验中接受评估，该试验针对复发或难治性多发性骨髓瘤 (rrMM) 患者。该公司还在 I 期试验中开发两个临床阶段的 ARC-SparX 项目；ACLX-001 针对 rrMM 中的 BCMA，ACLX-002 针对复发或难治性急性髓系白血病 (AML) 和高风险骨髓增生异常综合征 (MDS) 中的 CD123。除了多发性骨髓瘤 (MM) 之外，该公司还推进了其全资拥有的临床阶段、ACLX-002 和临床前管线项目组合，这些项目结合了其 D-Domain 技术。 D-Domain 旨在克服传统嵌合抗原受体 T 细胞 (CAR-T) 的局限性。
公司简介
公司代码ACLX
公司名称Arcellx Inc
上市日期Feb 04, 2022
CEOMr. Rami Elghandour
员工数量163
证券类型Ordinary Share
年结日Feb 04
公司地址800 Bridge Parkway
城市REDWOOD CITY
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94065
电话12403270603
网址https://www.arcellx.com/
公司代码ACLX
上市日期Feb 04, 2022
CEOMr. Rami Elghandour
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Rami Elghandour
Mr. Rami Elghandour
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.16M
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
21.66K
--
Ms. Michelle Gilson
Ms. Michelle Gilson
Chief Financial Officer
Chief Financial Officer
19.78K
+106.39%
Mr. Andrew H. Galligan
Mr. Andrew H. Galligan
Independent Director
Independent Director
5.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
424.00
--
Dr. Kavita Patel, M.D.
Dr. Kavita Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Olivia C. Ware
Ms. Olivia C. Ware
Independent Director
Independent Director
--
--
Ms. Jill Carroll
Ms. Jill Carroll
Independent Director
Independent Director
--
--
Ms. Kristin Myers
Ms. Kristin Myers
Independent Director
Independent Director
--
--
Dr. Christopher R. Heery, M.D.
Dr. Christopher R. Heery, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Rami Elghandour
Mr. Rami Elghandour
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.16M
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
21.66K
--
Ms. Michelle Gilson
Ms. Michelle Gilson
Chief Financial Officer
Chief Financial Officer
19.78K
+106.39%
Mr. Andrew H. Galligan
Mr. Andrew H. Galligan
Independent Director
Independent Director
5.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
424.00
--
Dr. Kavita Patel, M.D.
Dr. Kavita Patel, M.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2023
FY2023Q1
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
8.13M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月19日 周六
更新时间: 7月19日 周六
持股股东
股东类型
持股股东
持股股东
占比
Gilead Sciences Inc
12.20%
Fidelity Management & Research Company LLC
10.58%
Paradigm BioCapital Advisors LP
8.15%
The Vanguard Group, Inc.
7.22%
New Enterprise Associates (NEA)
6.80%
Other
55.06%
持股股东
持股股东
占比
Gilead Sciences Inc
12.20%
Fidelity Management & Research Company LLC
10.58%
Paradigm BioCapital Advisors LP
8.15%
The Vanguard Group, Inc.
7.22%
New Enterprise Associates (NEA)
6.80%
Other
55.06%
股东类型
持股股东
占比
Investment Advisor
42.05%
Investment Advisor/Hedge Fund
19.11%
Venture Capital
18.80%
Hedge Fund
14.57%
Corporation
12.20%
Private Equity
5.31%
Individual Investor
2.31%
Research Firm
1.48%
Bank and Trust
0.41%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
431
64.21M
116.51%
-2.54M
2025Q1
442
64.52M
117.16%
-1.34M
2024Q4
430
59.29M
107.92%
-4.74M
2024Q3
398
57.24M
106.64%
-6.94M
2024Q2
375
59.39M
111.67%
-2.79M
2024Q1
357
56.09M
107.90%
-1.83M
2023Q4
319
55.84M
115.04%
-754.57K
2023Q3
289
53.48M
111.00%
-3.40M
2023Q2
266
54.35M
113.58%
+3.00M
2023Q1
228
51.47M
108.59%
+6.59M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilead Sciences Inc
6.72M
12.2%
--
--
Apr 04, 2025
Fidelity Management & Research Company LLC
5.83M
10.58%
-1.63M
-21.87%
Mar 31, 2025
Paradigm BioCapital Advisors LP
4.49M
8.15%
+120.43K
+2.75%
Mar 31, 2025
The Vanguard Group, Inc.
3.98M
7.22%
+655.06K
+19.72%
Mar 31, 2025
New Enterprise Associates (NEA)
3.75M
6.8%
--
--
May 08, 2025
BlackRock Institutional Trust Company, N.A.
3.21M
5.83%
-37.95K
-1.17%
Mar 31, 2025
RA Capital Management, LP
3.04M
5.51%
+249.20K
+8.94%
Mar 31, 2025
Perceptive Advisors LLC
2.93M
5.31%
-552.41K
-15.88%
Mar 31, 2025
Vestal Point Capital, LP
2.39M
4.33%
+1.91M
+402.68%
Mar 31, 2025
SR One Capital Management, LP
2.35M
4.26%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
3.94%
Tema Oncology ETF
2.79%
ALPS Medical Breakthroughs ETF
2.45%
Harbor Human Capital Factor US Small Cap ETF
1.24%
SPDR S&P Biotech ETF
0.94%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
WisdomTree BioRevolution Fund
0.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
iShares Health Innovation Active ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.4%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比3.94%
Tema Oncology ETF
占比2.79%
ALPS Medical Breakthroughs ETF
占比2.45%
Harbor Human Capital Factor US Small Cap ETF
占比1.24%
SPDR S&P Biotech ETF
占比0.94%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.89%
WisdomTree BioRevolution Fund
占比0.63%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.54%
iShares Health Innovation Active ETF
占比0.47%
ProShares Ultra Nasdaq Biotechnology
占比0.4%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
